Eiger BioPharmaceuticals (NASDAQ:EIGR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a report issued on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Stock Performance

The company has a market capitalization of $2.55 million, a PE ratio of -0.03 and a beta of 1.83. The firm has a fifty day moving average of $4.85 and a two-hundred day moving average of $7.03. Eiger BioPharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $43.35.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.